RecruitingNCT06107582

Longitudinal Cohort of Pediatric Primary Immune Thrombocytopenia (ITP)

Clinical Characteristics, Prognosis and Prognostic Model of Pediatric Immune Thrombocytopenia: a Prospective, Multicenter, Observational Cohort Study


Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Enrollment

500 participants

Start Date

Nov 1, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

Immune thrombocytopenic purpura (ITP) is a kind of rare childhood disease that involve autoimmune destruction of platelets.The current Pediatric ITP cohorts are mostly based on single-center or multi-center cases, or cohorts with limited sample size in China. There is a lack of comprehensive and large-scale prospective cohort studies in pediatric ITP. The purpose of this study is to analyze the clinical characteristics of Pediatric ITP, the treatment methods, prognosis and prognostic model of these patients in China.


Eligibility

Min Age: 6 YearsMax Age: 17 Years

Inclusion Criteria2

  • Age 6-17 years old (including both ends), male and female;
  • Diagnosis of ITP.

Exclusion Criteria2

  • Secondary thrombocytopenia caused by various reasons, such as connective tissue disorders, bone marrow hematopoietic failure disease, myelodysplastic syndrome, malignancy, drugs, inherited thrombocytopenia, common variable immune deficiency, lymphoma, etc.;
  • The expected follow-up period is less than 3 months.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERdata collection

The study will collect basic information, diagnostic and treatment information from medical records and use questionnaire to measure the exposure of patients, and prospectively follow-up to collect the prognosis information.


Locations(1)

Chinese Academy of Medical Science and Blood Disease Hospital

Tianjin, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06107582


Related Trials